Dr. Meghan Chlebowski · Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Follow
Article1 min read·Published Nov 2026

Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO

link.springer.com shows its articles on its own site.

Read the article on link.springer.com ↗

Article · Nov 2026 · 1 min read

In brief

In brief

This review examines the clinical challenges of anticoagulation management during ECMO, focusing on the controversial use of antithrombin supplementation for heparin resistance in pediatric and neonatal patients. The authors analyze current monitoring strategies and therapeutic interventions amid limited evidence and high practice variability across centers.

Written by the GCMD Library team from the article.

Meghan M. Chlebowski

During extracorporeal membrane oxygenation (ECMO), a delicate balance is required to titrate systemic anticoagulation to prevent thrombotic complications within the circuit and prevent bleeding in the patient. Despite focused efforts to achieve this balance, the frequency of both thrombotic and bleeding events remains high. Anticoagulation is complicated to manage in this population due to the complexities of the hemostatic system that are compounded by age-related developmental hemostatic changes, variable effects of the etiology of critical illness on hemostasis, and blood-circuit interaction. Lack of high-quality data to guide anticoagulation management in ECMO patients results in marked practice variability among centers. One aspect of anticoagulation therapy that is particularly challenging is the use of antithrombin (AT) supplementation for heparin resistance. This is especially controversial in the neonatal and pediatric population due to the baseline higher risk of bleeding in this cohort. The indication for AT supplementation is further compounded by the potential inaccuracy of the diagnosis of heparin resistance based on the standard laboratory parameters used to assess heparin effect. With concerns regarding the adverse impact of bleeding and thrombosis, clinicians and institutions are faced with making difficult, real-time decisions aimed at optimizing anticoagulation in this setting. In this clinically focused review, the authors discuss the complexities of anticoagulation monitoring and therapeutic intervention for patients on ECMO and examine the challenges surrounding AT supplementation given both the historical and current perspectives summarized in the literature on these topics.

Read it at the source ↗

Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.